PD-1 inhibitor promising in BCG-unresponsive NMIBC
In this video interview with Urology Times, Arjun V. Balar, MD, PhD, discusses the current role of PD-1 inhibitors, their mechanism of action, and his own impression of recently presented phase II study data.
The PD-1 inhibitor pembrolizumab (KEYTRUDA) showed encouraging results in a phase II study of patients with high-risk, BCG-unresponsive nonmuscle-invasive bladder cancer with carcinoma in situ (CIS), researchers reported at the Society of Urologic Oncology annual meeting in Phoenix.
“What we have seen in this interim analysis, with a median follow-up of 14 months, is that the complete response rate in the bladder for patients with CIS, with or without papillary disease, is 38.8%,” said first author Arjun V. Balar, MD, PhD, of NYU Langone’s Perlmutter Cancer Center. “To see a 38.8% complete response rate, I think is quite promising, but we need longer term follow-up to determine how durable these responses are.”
In this video interview with Urology Times, Dr. Balar discusses the current role of PD-1 inhibitors, their mechanism of action, and his own impression of the current phase II study data.
Dr. Balar receives grants/research support from Genentech/Hoffman-La Roche, Merck, and Astra Zeneca; and is a consultant for Astra Zeneca/MedImmune, Genentech/Hoffman-La Roche, Merck, Pfizer, Incyte, and EMD Serono.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.
